STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York ...
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind ®, a leading mental health care company, is launching on August 10, 2019 Genomind Professional PGx Express™, a new, more focused report and set of ...
SALT LAKE CITY, June 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, acknowledges the release of a final local coverage ...
Pharmacogenomic (PGx) testing identifies variants in a patient's DNA that affect how the individual responds to specific medications. PGx testing can help increase the quality of patient care and ...
Genomind Supports New Reimbursement Initiatives and Patient Access to Mental Health Pharmacogenomic Tests with PGx Report Focused on Anxiety and Depression New CORE Depression and Anxiety Report ...
SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback